Abstract
BackgroundThe mean platelet volume/platelet count ratio (MPV/PC) ratio based on the preoperative peripheral MPV and PCcan be used to predict the prognosis of multiple malignant tumors.ObjectiveTo evaluate the prognostic value of MPV/PC in cervical cancer patients.MethodsThis study enrolled 408 patients who had undergone radical surgery for cervical cancer and evaluated the correlation of MPV/PC with patient prognosis in the primary cohort and validation cohort. Additionally, independent prognostic factors were incorporated to construct the prognostic nomogram, and the area under the receiver operating characteristic (ROC) curve (AUC) value was calculated to analyze the prognostic predictive ability of the nomogram.ResultsIn the primary cohort, Kaplan–Meier survival analysis indicated that the overall survival (OS) for patients with MPV/PC ≤ 0.41 was significantly lower than that in patients with MPV/PC > 0.41. MPV/PC was an independent prognostic factor for resectable cervical cancer patients. Compared with neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR) or monocyte/lymphocyte ratio (MLR), the AUC values of MPV/PC in predicting the 3- and 5-year survival rates for cervical cancer patients were greater. Similar results were verified in the validation cohort. Subsequently, the nomogram constructed based on MPV/PC, International Federation of Gynecology and Obstetrics (FIGO) classification and lymphovascular invasion performed well to accurately predict the prognosis of cervical cancer patients. The 3- and 5-year survival rates predicted by the nomogram were highly consistent with the real observations. Similar results were also displayed in the validation cohort.ConclusionsMPV/PC may be used as a novel independent prognostic factor for patients with resectable cervical cancer. Compared with the FIGO classification system, the nomogram integrating MPV/PC maybe reliably predict the survival of cervical cancer patients after radical surgery.
Highlights
The morbidity and mortality of cervical cancer rank 4th among female malignant tumors worldwide [1]
mean platelet volume/platelet count ratio (MPV/platelet count (PC)) may be used as a novel independent prognostic factor for patients with resectable cervical cancer
Compared with the Federation of Gynecology and Obstetrics (FIGO) classification system, the nomogram integrating mean platelet volume (MPV)/PC maybe reliably predict the survival of cervical cancer patients after radical surgery
Summary
The morbidity and mortality of cervical cancer rank 4th among female malignant tumors worldwide [1]. Approximately 527,600 new cervical cancer cases and 265,700 cervical cancer-related deaths are reported annually [1]; among them, more than 80% of cases come. 98,900 new cervical cancer cases and 30,500 deaths occurred in China in 2015 [2]. The International Federation of Gynecology and Obstetrics (FIGO) classification system is mainly used to judge the clinical prognosis of cervical cancer. The FIGO classification system is restricted in judging the prognosis of cervical cancer patients. Other indexes must be applied (such as hematological indexes, pathological type, histological grade, tumor infiltration depth or scope, and lymph node metastasis (LNM) staging) to comprehensively judge the patient prognosis. The mean platelet volume/platelet count ratio (MPV/PC) ratio based on the preoperative peripheral MPV and PCcan be used to predict the prognosis of multiple malignant tumors
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
